In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hy BioPharma Inc.

www.hybiopharma.com

Latest From Hy BioPharma Inc.

Hy BioPharma Inc.

Hy BioPharma is developing hypericin phototherapeutics for cancers and autoimmune disorders. The Israeli/US start-up is also in Phase I/IIb trials for an oral formulation of hypericin for possible use in combination therapy with Temodar for the treatment of glioblastoma.
BioPharmaceutical

Start-Up Previews (07/2008)

A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Hy BioPharma Inc.
  • Senior Management
  • Michael Steinberg, CEO
    Zadik Hazan, MD, VP, Res.
  • Contact Info
  • Hy BioPharma Inc.
    Phone: (215) 918-3336
    2500 York Rd.
    Ste. 100
    Jamison, PA 18929
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register